BioStock: CombiGene focuses on the pain project

In CombiGene’s Q3 report, the terminated agreement with Spark Therapeutics takes up considerable space, for obvious reasons. However, the report highlights that the gene therapy company is now focusing on the COZY1 pain project. They have chosen both a production partner and a collaborator for upcoming preclinical toxicology studies, along with indications for the clinical trial program.

Read the article at biostock.se:

https://www.biostock.se/en/2023/11/combigene-focuses-on-the-pain-project/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/